# MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/MNKD/mannkind-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: MNKD
Company: MannKind
Source: MannKind
Published: 2026-05-06 20:01 EST
Original Source URL: https://investors.mannkindcorp.com
## Summary

Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza ®  pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow ™

## Article Body
Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza ®  pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow ™
## Recent Company News
- 2026-06-03 10:05 EST — [MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF](https://biopharmsignal.com/news/MNKD/mannkind-enters-data-rich-development-period-with-completion-of-randomization-in-phase-1b-inflo-1-study-and-enrollment-of-first-patient-in-phase-2-inflo-2-trial-for-nintedanib-dpi-in-patients-with-ipf) — Source: MannKind
- 2026-05-29 18:00 EST — [MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval](https://biopharmsignal.com/news/MNKD/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval) — Source: MannKind
- 2026-05-29 16:30 EST — [MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes](https://biopharmsignal.com/news/MNKD/mannkind-announces-fda-approval-of-afrezzar-the-first-and-only-inhaled-mealtime-insulin-for-use-in-children-and-adolescents-aged-6-and-older-living-with-diabetes) — Source: MannKind
- 2026-05-27 20:00 EST — [MannKind to Present at Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/MNKD/mannkind-to-present-at-jefferies-global-healthcare-conference) — Source: MannKind
- 2026-05-27 13:05 EST — [MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems](https://biopharmsignal.com/news/MNKD/mannkind-to-showcase-new-data-at-ada-2026-advancing-understanding-of-inhaled-insulin-afrezzar-in-pediatric-care-pregnancy-and-use-with-automated-insulin-delivery-aid-systems) — Source: MannKind
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)